1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 79,10 | 79,25 | 23:00 | |
| 78,90 | 79,35 | 22:00 |
► 01.04.: | | | | | | | | |
► 31.03.: | | | | | | | | | 17:30
► Aktueller BIONTECH Börsenkurs + Xetra-Orderbuch
► 31.03.: | | | | | | | | | 17:30
► Aktueller BIONTECH Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 82,50 | 160 | |||
| 82,00 | 300 | |||
| 81,00 | 52 | |||
| 80,55 | 1.000 | |||
| 80,40 | 130 | |||
| 80,00 | 86 | |||
| 79,50 | 100 | |||
| 79,45 | 116 | |||
| 78,25 | 216 | |||
| 77,95 | 108 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/22ua.htm [/URL] | ||||
| 224 | 77,70 | |||
| 15 | 76,60 | |||
| 116 | 74,15 | |||
| 26 | 74,10 | |||
| 40 | 73,50 | |||
| 80 | 73,10 | |||
| 13 | 72,55 | |||
| 50 | 72,50 | |||
| 250 | 72,25 | |||
| 200 | 72,05 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.014 | 2,237 | 2.268 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:46:24 | 76,55 | 100 |
| 15:46:11 | 76,70 | 10 |
| 15:45:16 | 76,65 | 16 |
| 15:45:12 | 76,65 | 20 |
| 15:36:05 | 76,25 | 14 |
| 15:31:02 | 76,20 | 13 |
| 15:30:18 | 76,03 | 43 |
| 15:29:47 | 76,05 | 42 |
| 15:03:59 | 76,15 | 36 |
| 14:33:50 | 76,35 | 84 |
| 14:32:51 | 76,40 | 29 |
| 14:32:27 | 76,35 | 142 |
| 14:32:27 | 76,45 | 41 |
| 14:32:27 | 76,30 | 2.155 |
| 14:32:27 | 76,30 | 235 |
| 14:31:27 | 76,10 | 46 |
| 14:30:19 | 76,00 | 71 |
| 14:30:19 | 76,05 | 9 |
| 14:29:45 | 76,25 | 79 |
| 14:22:52 | 76,05 | 44 |
| Tagesumsatz Xetra | -0,05 -0,06 % | 37.198 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:16 | BioNTech SE - 6-K, Report of foreign issuer | 22 | SEC Filings | ||
| 21:10 | BioNTech telegraphs closure of Singapore vaccine facility amid efforts to 'align capacity' | 46 | FiercePharma | ||
| BIONTECH Aktie jetzt für 0€ handeln | |||||
| 19:31 | BRANDMELDUNG bei Biontech: 0,2% Plus und das könnte erst der Anfang sein - Was das für Ihr Depot bedeutet | Hebelschein-Spekulant | |||
| 16:21 | Biontech-Investoren steigen bei Doctolib ein | 108 | manager-magazin.de | ||
| 09:14 | Pfizer and BioNTech halt U.S. COVID-19 vaccine study after recruitment struggles | 75 | Japan Times |
1 2 3 4 5 Weiter >>
781 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 17:15 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 13:26 | Resverlogix Corp.: Resverlogix Corp. Announces Issuance of MCTO by ASC | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the... ► Artikel lesen | |
| 19:06 | Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights | Business Wire | Regulatory News:
Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.
2025 business... ► Artikel lesen | |
| 14:38 | Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System | ACCESS Newswire | - This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia... ► Artikel lesen | |
| 13:36 | Context Therapeutics Inc.: Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | GlobeNewswire (Europe) | Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIONTECH SE ADR finden Sie auf Wallstreet Online.